SGLT2 inhibitors

KDIGO CKD guidelines 2024

Latest Kidney Disease KDIGO Guideline Highlights: What Clinicians Need to Know

The 2024 KDIGO Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease (CKD) introduces the most significant updates since 2012. The new recommendations reflect major advances in risk stratification, GFR estimation, and disease-modifying therapies that meaningfully slow CKD progression and reduce cardiovascular risk. This summary highlights the essential changes relevant to primary […]

Latest Kidney Disease KDIGO Guideline Highlights: What Clinicians Need to Know Read More »

SGLT2i use in Heart failure

SGLT2 Inhibitors in Heart Failure: Underused Even Among Cardiologists?

A Missed Opportunity: SGLT2 inhibitors in Heart Failure Care Sodium-glucose cotransporter 2 inhibitors (SGLT2i) have transformed heart failure management, reducing both hospitalizations and cardiovascular deaths across the ejection fraction spectrum. Guidelines now recommend SGLT2i as foundational therapy for patients with heart failure—yet real-world prescribing still lags far behind. A new retrospective cohort study of over

SGLT2 Inhibitors in Heart Failure: Underused Even Among Cardiologists? Read More »